Biodesix develops simple theranostic blood test for lung cancer
This article was originally published in Clinica
Executive Summary
US firm Biodesix is developing a theranostic blood test for non-small-cell lung cancer (NSCLC) that it claims will be the first of its kind to not require a tissue sample from the patient.